Basics Ardelyx, Inc. Ardelyx Inc is a biotechnology company focused on the discovery, development, and commercialization of molecule and polymeric therapeutics to treat the gastrointestinal tract and cardiorenal diseases. IPO Date: June 19, 2014 Sector: Healthcare Industry: Biotech Market Cap: $921.13M Activated in VL: True Average Daily Range Avg Daily Range: $0.23 | 3.26% Avg Daily Range (30 D): $0.14 | 3.48% Avg Daily Range (90 D): $0.14 | 2.91% Institutional Daily Volume Avg Daily Volume: 2.35M Avg Daily Volume (30 D): 5.4M Avg Daily Volume (90 D): 4.33M Trade Size Avg Trade Size (Sh.): 273 Avg Trade Size (Sh.) (30 D): 224 Avg Trade Size (Sh.) (90 D): 200 Institutional Trades Total Inst.Trades: 1,360 Avg Inst. Trade: $2.24M Avg Inst. Trade (30 D): $1.77M Avg Inst. Trade (90 D): $1.87M Avg Inst. Trade Volume: .44M Avg Inst. Trades (Per Day): 1 Market Closing Trades Avg Closing Trade: $3.02M Avg Closing Trade (30 D): $1.96M Avg Closing Trade (90 D): $2.02M Avg Closing Volume: 565.36K     News Jun 2, 2025 @ 5:50 PM INVESTOR ALERT: Pomerantz Law Firm Investigates Cl... Source: N/A May 21, 2025 @ 12:00 PM Ardelyx to Participate at the Jefferies Global Hea... Source: N/A Apr 24, 2025 @ 12:01 PM Ardelyx Announces Three Abstracts Accepted for Pos... Source: N/A Feb 19, 2025 @ 1:01 PM Ardelyx to Present at the TD Cowen 45th Annual Hea... Source: Ardelyx, Inc. Jan 6, 2025 @ 1:00 PM Ardelyx to Present at the 43rd Annual J.P. Morgan ... Source: N/A Financials   TTM Q1 2025 Q4 2024 Basic EPS $-.22 $-.17 $.02 Diluted EPS $-.22 $-.17 $.02 Revenue $ 361.71M $ 74.11M $ 116.13M Gross Profit $ 305.98M $ 61.81M $ 97.87M Net Income / Loss $ -53.76M $ -41.14M $ 4.65M Operating Income / Loss $ -39.62M $ -36.35M $ 8.13M Cost of Revenue $ 55.73M $ 12.3M $ 18.26M Net Cash Flow $ -5.34M $ -34.12M $ 17.5M PE Ratio